News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
858,279 Results
Type
Article (87413)
Company Profile (739)
Press Release (770109)
Multimedia
Podcasts (197)
Webinars (28)
Section
Business (232768)
Career Advice (4143)
Deals (39873)
Drug Delivery (144)
Drug Development (91175)
Employer Resources (205)
FDA (18253)
Job Trends (17422)
News (396850)
Policy (39843)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3002)
Academic (1)
Accelerated approval (31)
Adcomms (30)
Allergies (121)
Alliances (56794)
ALS (153)
Alzheimer's disease (1749)
Antibody-drug conjugate (ADC) (312)
Approvals (18366)
Artificial intelligence (467)
Autoimmune disease (155)
Automation (31)
Bankruptcy (402)
Best Places to Work (12512)
BIOSECURE Act (23)
Biosimilars (204)
Biotechnology (457)
Bladder cancer (145)
Brain cancer (52)
Breast cancer (538)
Cancer (4277)
Cardiovascular disease (301)
Career advice (3568)
Career pathing (41)
CAR-T (289)
CDC (36)
Celiac Disease (1)
Cell therapy (760)
Cervical cancer (29)
Clinical research (76105)
Collaboration (1603)
Company closure (4)
Compensation (990)
Complete response letters (64)
COVID-19 (2927)
CRISPR (85)
C-suite (732)
Cystic fibrosis (143)
Data (5410)
Decentralized trials (2)
Denatured (73)
Depression (114)
Diabetes (340)
Diagnostics (6976)
Digital health (23)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (251)
Drug pricing (161)
Drug shortages (19)
Duchenne muscular dystrophy (197)
Earnings (97997)
Editorial (57)
Employer branding (25)
Employer resources (173)
Events (132799)
Executive appointments (824)
FDA (20617)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (24)
Funding (1269)
Gene editing (183)
Generative AI (46)
Gene therapy (601)
GLP-1 (932)
Government (5323)
Grass and pollen (4)
Guidances (276)
Healthcare (20777)
HIV (43)
Huntington's disease (46)
IgA nephropathy (79)
Immunology and inflammation (267)
Immuno-oncology (58)
Indications (80)
Infectious disease (3146)
Inflammatory bowel disease (203)
Inflation Reduction Act (14)
Influenza (95)
Intellectual property (198)
Interviews (816)
IPO (17808)
IRA (45)
Job creations (5198)
Job search strategy (2866)
JPM (66)
Kidney cancer (16)
Labor market (92)
Layoffs (639)
Leadership (37)
Legal (10091)
Liver cancer (87)
Longevity (13)
Lung cancer (582)
Lymphoma (332)
Machine learning (41)
Management (66)
Manufacturing (714)
MASH (159)
Medical device (14421)
Medtech (14451)
Mergers & acquisitions (22742)
Metabolic disorders (1062)
Multiple sclerosis (149)
NASH (22)
Neurodegenerative disease (327)
Neuropsychiatric disorders (79)
Neuroscience (2891)
Neurotech (1)
NextGen: Class of 2026 (7686)
Non-profit (5079)
Now hiring (65)
Obesity (520)
Opinion (325)
Ovarian cancer (150)
Pain (153)
Pancreatic cancer (170)
Parkinson's disease (260)
Partnered (33)
Patents (394)
Patient recruitment (414)
Peanut (56)
People (66277)
Pharmaceutical (133)
Pharmacy benefit managers (20)
Phase 1 (23595)
Phase 2 (33119)
Phase 3 (24815)
Pipeline (4281)
Policy (283)
Postmarket research (3544)
Preclinical (10586)
Press Release (72)
Prostate cancer (203)
Psychedelics (51)
Radiopharmaceuticals (278)
Rare diseases (792)
Real estate (7422)
Recruiting (80)
Regulatory (28227)
Reports (63)
Research institute (2695)
Resumes & cover letters (651)
Rett syndrome (21)
RNA editing (21)
RSV (63)
Schizophrenia (139)
Series A (224)
Series B (160)
Service/supplier (25)
Sickle cell disease (85)
Special edition (27)
Spinal muscular atrophy (175)
Sponsored (47)
Startups (4323)
State (2)
Stomach cancer (14)
Supply chain (74)
Tariffs (76)
The Weekly (122)
Vaccines (998)
Venture capital (91)
Weight loss (338)
Women's health (71)
Worklife (22)
Date
Last 7 days (472)
Last 30 days (1733)
Last 365 days (25234)
2026 (2379)
2025 (25545)
2024 (34037)
2023 (42567)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51337)
2018 (39122)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1279)
Alabama (85)
Alaska (6)
Arizona (288)
Arkansas (8)
Asia (51120)
Australia (9002)
California (9724)
Canada (2473)
China (1055)
Colorado (306)
Connecticut (389)
Delaware (295)
Europe (116899)
Florida (1256)
Georgia (253)
Hawaii (4)
Idaho (65)
Illinois (652)
India (56)
Indiana (445)
Iowa (21)
Japan (338)
Kansas (133)
Kentucky (25)
Louisiana (14)
Maine (59)
Maryland (1256)
Massachusetts (7303)
Michigan (244)
Minnesota (452)
Mississippi (5)
Missouri (78)
Montana (28)
Nebraska (29)
Nevada (106)
New Hampshire (57)
New Jersey (2551)
New Mexico (29)
New York (2550)
North Carolina (1410)
North Dakota (9)
Northern California (4773)
Ohio (257)
Oklahoma (18)
Oregon (51)
Pennsylvania (1869)
Puerto Rico (22)
Rhode Island (33)
South America (1658)
South Carolina (13)
South Dakota (1)
Southern California (3750)
Tennessee (58)
Texas (1358)
United States (33785)
Utah (209)
Vermont (1)
Virginia (168)
Washington D.C. (54)
Washington State (818)
West Virginia (2)
Wisconsin (82)
858,279 Results for "2seventy bio".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
CAR-T
Regeneron Cans 2seventy-Acquired CAR T Candidate for Lymphoma in ‘Strategic’ Move
The discontinued CAR T therapy bbT369 came to Regeneron when the pharma bought all of 2seventy bio’s pipeline assets for $5 million upfront in January 2024.
October 24, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
BMS Buys Abecma Partner 2seventy for $286M, Ending Cost Sharing Agreement
Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.
March 11, 2025
·
3 min read
·
Tristan Manalac
Genetown
2seventy bio to Participate in Upcoming Investor Conferences - May 23, 2024
2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will present at the following upcoming investor conferences.
May 23, 2024
·
1 min read
Press Releases
2seventy bio to Participate in the 2025 TD Cowen Healthcare Conference
February 25, 2025
·
1 min read
Press Releases
2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
March 11, 2025
·
19 min read
Genetown
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
2seventy bio, Inc., announced the completion of the asset purchase agreement by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all oncology and autoimmune research and development programs and has hired approximately 160 employees from 2seventy bio as part of their newly launched cell medicines business.
April 1, 2024
·
4 min read
Deals
2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
2seventy bio, Inc., announced the completion of an asset purchase agreement by Novo Nordisk. Under the terms of the APA, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for the treatment of autoimmune disease.
June 26, 2024
·
4 min read
Business
2seventy bio Reports First Quarter 2024 Financial Results and Recent Operational Progress
2seventy bio, Inc., reported financial results and recent highlights for the first quarter ended March 31, 2024.
May 8, 2024
·
22 min read
Business
2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024.
May 3, 2024
·
1 min read
Press Releases
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb
May 8, 2025
·
19 min read
1 of 85,828
Next